Morgan Stanley analyst Sean Laaman raised the firm’s price target on Immunocore (IMCR) to $36 from $34 and keeps an Equal Weight rating on the shares.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IMCR:
- Immunocore price target raised to $37 from $36 at Mizuho
- Immunocore Holdings: Strong Q3 Performance and Strategic Advancements Justify Buy Rating
- Immunocore presents Phase 1 data for hepatitis B candidate at AASLD
- Immunocore Reports Strong Growth in Q3 2025
- Immunocore reports Q3 EPS 0c, consensus (24c)